MiliaryMycobacterium bovisInduced by Intravesical Bacille Calmette-Guérin Immunotherapy
- 1 November 1992
- journal article
- case report
- Published by American Thoracic Society in American Review of Respiratory Disease
- Vol. 146 (5_pt_1) , 1330-1333
- https://doi.org/10.1164/ajrccm/146.5_pt_1.1330
Abstract
Intravesical instillation of bacille Calmette-Guérin (BCG), an attenuated strain of Mycobacterium bovis, is the treatment of choice for many patients with bladder cancer. In a small percentage, this therapy is associated with systemic side effects including pneumonitis. It is uncertain whether these systemic manifestations are due to dissemination of infection or due to hypersensitivity, an etiologic distinction that has important therapeutic implications. We report the first case in which miliary M. bovis was proven to be the responsible mechanism, by culture of M. bovis biovar BCG from a transbronchial lung biopsy and complete resolution on anti-tuberculous chemotherapy.Keywords
This publication has 9 references indexed in Scilit:
- Fatal Sepsis Following Intravesical Bacillus Calmette-Guerin Administration for Bladder CancerJournal of Urology, 1990
- Pulmonary disease following intravesical BCG treatment.Thorax, 1990
- Biology and Management of Bladder CancerNew England Journal of Medicine, 1990
- Hypersensitivity reaction to bacillus calmette-guérin treated with plasmapheresisThe American Journal of Medicine, 1989
- Miliary Tuberculosis due to Intravesical Bacillus Calmette-Guerin TherapyChest, 1988
- Toxicity of intravesical BCG and its management in patients with superficial bladder tumorsCancer, 1987
- Complications of Bacillus Calmette-Guerin Immunotherapy in 1,278 Patients with Bladder CancerJournal of Urology, 1986
- Granulomatous hepatitis as a late complication of BCG immunotherapyCancer, 1980
- Pigeon Breeder's DiseaseRadiology, 1968